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Summary In a blind study, 518 serum samples were assayed for serum levels of mammary serum antigen
(MSA) by an enzyme immunoassay (EIA) using the 3E1.2 monoclonal antibody. Using 300IU as the
arbitrary cut off to distinguish normal from abnormal individuals, 75% of patients with primary Stage I
carcinoma of the breast (n = 12), 89% of those with Stage II (n =9) and 93% of those with Stage IV (n =57)
had elevated levels of MSA. A relationship was observed between the level of MSA and stage of disease, and
therefore with the extent of tumour burden. Levels of MSA were also determined in a series of 19 patients
undergoing chemotherapy for breast cancer. Over a 2-24 month period, the change of MSA levels
corresponded with the clinical course of the disease in 17 (89%) cases. MSA levels were also raised in some
patients with ovarian, colon, lung and kidney cancer, but the average level was lower than in patients with
breast cancer. A comparison of CEA and MSA levels in these patients revealed that MSA was a substantially
better marker for breast cancer than CEA. The results of this study demonstrate that MSA levels are elevated
in patients with breast cancer and may provide a useful means of following the clinical course of patients with
this disease.
Previously we have reported the production of a monoclonal
antibody 3E1.2, raised against a fresh primary carcinoma of
the breast (Stacker et al., 1985a). Immunoperoxidase staining
has shown that the breast tumour-associated antigen defined
by the monoclonal antibody is present on >90% of breast
cancers, and to a lesser extent on normal breast epithelium
and other normal tissues (Stacker et al., 1985a). 3E1.2 also
detects molecules present in human serum; a high molecular
weight glycoprotein which we have called mammary serum
antigen (MSA). A competitive enzyme immunoassay was
developed to quantify the level of circulating MSA in serum.
MSA has been found to be elevated in patients with
localised and advanced breast cancer compared to normal
individuals (Stacker et al., 1985b). In addition, changes in
MSA levels have been shown to correlate with the clinical
course in patients with advanced breast cancer (Stacker et
al., 1987).
Other workers have produced monoclonal antibodies
which define high molecular weight glycoproteins in the
serum of patients with breast cancer (Hayes et al., 1985;
Papasidero et al., 1984; Burchell et al., 1984; lacobelli et al.,
1986). 3E1.2 can be distinguished from these monoclonal
antibodies by its lack of reactivity with high molecular
weight glycoproteins in human milk and milk fat globule
membranes (Stacker et al., 1987). In this paper we describe
the MSA levels found in three separate panels of coded
serum samples. Included in this study are: (i) the evaluation
of MSA levels in non-breast cancers and non-malignant
disorders; (ii) the use of MSA levels for monitoring the
clinical course of disease in patients with breast cancer; and
(iii) the comparison of MSA and CEA levels in the serum of
patients with breast cancer and other diseases.
Materials and methods
Serum samples
Three separate panels of serum samples were obtained from
the laboratories of Hoffman-La Roche, Basel, Switzerland
and the Cancer Institute, Melbourne, Australia.
(Panel A) This panel contained 379 samples, consisting of
serum collected from normal individuals, including smokers
(10) and non-smokers (20); pregnant women (30); patients
with breast cancer; samples collected pre-operatively (21) and
post-operatively (106); patients with other cancers (95); and
non-malignant disorders (97). These samples were obtained
from the laboratories of Hoffman-La Roche and tested in
their laboratories.
(Panel B) A panel of 120 serum samples which consisted
of 50 normal individuals (sex unspecified), 39 patients with
breast cancer, 15 patients with other types of cancer and 16
patients with non-malignant disorders. These samples were
obtained from Hoffman-La Roche and tested at Australian
Med-Research Industries.
(Panel C) Serum was also obtained from 19 patients
undergoing treatment for breast cancer at the Cancer
Institute, Melbourne and tested at the Research Centre for
Cancer and Transplantation. Samples were collected twice
from each patient, over an interval of two months to two
years. These patients were clinically assessed at the time of
the second bleed and classified as having disease that
progressed (8 patients), stabilised (5 patients) or regressed (6
patients) by accepted criteria (Beahrs & Myers, 1983). A
50% change in the original MSA level was considered
significant.
Serum samples were obtained from clotted blood and
stored at -20°C until use. Samples from Hoffman-La Roche
were transported in dry ice to Australia, and no thawing was
evident on arrival. The criteria for staging and disease status
is in accord with accepted definitions (Beahrs & Myers,
1983). Samples were obtained coded, and the code not
broken until the completion of testing.
Monoclonal antibody
The murine monoclonal antibody 3E1.2 was raised against
fresh human carcinoma of the breast using standard somatic
cell hybridisation techniques (Stacker et al., 1985a). The
hybridoma was subsequently grown intraperitoneally in mice
and obtained in ascites form. Purification of the antibody
from ascites fluid was achieved by treatment with freon
(CICF2CCL2F; Aldrich Chemical Co., Milwaukee, WI,
USA) to remove lipid, then dialysis against 5mM Tris-HCl
(pH 7.5) and the precipitate recovered. The semi-purified
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antibody was resuspended in 20mM borate buffer pH8.0,
0.3 M NaCl and stored at -70°C prior to use.
Assays
Serum MSA levels were determined by a competitive EIA
(Stacker et al., 1987) with the variation that an avidin-biotin
system (Amersham International, UK) was used to develop
the assay. A cut-off level of 300 inhibition units (IU) was
used for the MSA assay as it is the mean+2 standard
deviations of the level found in normal females by a previous
study (Stacker et al., 1987). The inhibition units are an
arbitrary scale of measurement which represents the
concentration of MSA in a serum sample. Serum CEA levels
were determined by an enzyme immunoassay (Hoffman-La
Roche, Basel, Switzerland). A cut-off level of 2.5 ngml
was employed for the CEA assay.
Results
Panel A samples (n =384)
Normals MSA levels were <300IU in 28/30 normal
individuals consisting of 10 smokers and 20 non-smokers
(Table I, Figure 1). In general the serum MSA level in this
group was low, with a median MSA level of 94IU for non-
smokers and 104IU for smokers, although 2/30 individuals
had MSA levels >300IU being the value selected to
distinguish normal from abnormal individuals. These two
normal individuals, with MSA levels >300IU, were both
smokers and had serum levels of 311 and 468 IU, their
respective CEA levels were 2.5ngml-1, the upper limit of
normal, and 1.8ngml-1. None of the normal sera examined
had raised CEA levels (Table I). Pregnant women (30) were
also examined and found to have a median MSA level 76IU,
with 4 (13%) having elevated MSA levels (315, 356, 359 and
588IU), however, CEA levels were not raised in any of these
(range 1.1-1.3 ngml- 1) (Table I).
Breast cancer In contrast to normal individuals, serum
MSA levels were elevated in the majority of patients with
active breast cancer (Table I). Of 21 patients with localised
breast cancer (stages I and II) 81% (17) had levels >300IU,
with median levels of 653IU and 764IU respectively. The
majority of patients (88-100%) with metastatic disease had
raised levels of MSA; these consisted of 92% with bone
metastases (n=25), 100% with liver metastases (n=6), 100%
with lung/pleural metastases (n =10) and 88% of patients
with multiple metastases (n=-16) (Table I, Figure 2).
Although the median levels of metastatic disease were higher
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Figure 1 Levels of MSA found in serum samples from normal
individuals (smokers and non-smokers), pregnant women, breast
cancer patients with no evidence of disease (NED CaB), breast
cancer patients with local recurrence (LR CaB), patients with
carcinoma of the colon (CaCo), kidney (CaKi), ovary (CaOv)
and Lung (CaLu). Patients previously having carcinoma of the
kidney but now with no evidence of disease are indicated (*), 0/9
had levels >300IU. The cut off level of 300IU is indicated by a
horizontal line.
than those of localised breast cancer, those with multiple
metastases (median 3630IU) had greater median MSA levels
than patients with bone metastases (median 1374IU) (Table
I). Of 30 individuals with a past history of breast cancer, but
now with no clinical evidence of disease, 60% (18) had MSA
levels >300IU (median 366). Furthermore, 74% of breast
cancer patients with local recurrence (n= 19) had levels
>300IU, with a median level of 1561 IU (Table I, Figure 1).
CEA was found to be a poorer marker for breast cancer
than MSA (Table I). Elevated levels of CEA (>2.5ngml-1)
were found in fewer patients, in particular those with
Table I Levels of MSA and CEA in normal individuals and breast cancer patients
MSA level
Number of CEA level
Group patients Median(IU) >300IU(%) >2.5ngml-' (%)
Normal individuals
Smokers 10 104 20 0
Non-smokers 20 94 0 0
Pregnant 30 76 13 0
Total 60 101 10 2
Breast cancer
Stage I 12 653 75 14
Stage II 9 764 89 47
Bone metastases 25 1374 92 60
Liver metastases 6 2794 100 50
Multiple metastases 16 3630 88 82
Lung and pleural metastases 10 2361 100 40
Local recurrence 19 1561 74 32
No evidence of diseasea 30 366 60 3
aPatients previously having breast cancer but now with no clinically detectable disease.
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Figure 2 Levels of MSA found in serum samples of breast
cancer patients: (i) Stage I = 1, Stage II =2, (ii) metastases present
in either the liver, lung and pleura, bone or multiple sites. The
cut off level of 300IU is indicated by a horizontal line.
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localised disease (Table I, Figure 3a). Only 3 patients with
active breast cancer had CEA levels >2.5ngmml1 but
normal MSA levels (Figure 3a, b). Whereas MSA levels were
>300IU in 40 cases with normal CEA levels (Figure 3a,b).
No correlation was observed between CEA and MSA levels
in patients with localised (Figure 3a) or advanced breast
cancer (Figure 3b).
Non-breast tumours MSA levels were determined in patients
(n=100) with 4 non-breast epithelial tumours (Table II,
Figure 1). Of 20 patients with ovarian cancer 14 (70%) had
levels >300IU (median 598IU). MSA was also elevated in
tumours of the colon (60%), lung (71%), and kidney (59%),
but in general the median level was lower (Table II).
Elevated levels of CEA were also found in this group, in
particular 60% of patients with colon cancer (n = 30) and
67% of patients with lung cancer (n =30) had levels
>2.5 ngml-1. Raised levels of CEA were also detected in
100 1000
CEA (ng ml-1)
Figure 3 Correlation between MSA and CEA serum levels. (a)
Patients with Stage I breast cancer, Stage II breast cancer and
local recurrence of breast cancer (n=40, r2=0.058); (b) Patients
with metastatic breast cancer (n=58, r2=0.016). The cut off
levels of 300IU and 2.5ngml-I are indicated.
12% of patients with cancer of the kidney (n= 17) and 30%
of those with ovarian cancer (n =23) (Table II). No correla-
tion was found between CEA and MSA levels in patients
with ovarian cancer (correlation coefficient, r2=0.015),
colon cancer (r2 2 0.006), kidney cancer (r2 =0.087) and
lung cancer (r2=0.008).
MSA levels in non-malignant disease In patients with non-
malignant diseases (n=97) levels of MSA and CEA were
elevated in 36% and 39% of cases respectively (Table II,
Table II Levels of MSA and CEA in normal individuals and patients with non-malignant
diseases, breast cancer and other cancers
MSA level
Number of CEA level
Group patients Median (IU) >300IU (%) >2.5ngml-1 (%)
Normal 30 101 7 0
Breast cancer (total)a 98 1642 85 46
Ovarian cancer 20 598 70 30
Colon cancer 30 354 60 60
Lung cancer 28 401 71 67
Kidney cancer 17 366 59 12
Non-malignant diseasesb 97 159 36 39
'Includes patients with stage I, II and IV disease, metastatic disease and local recurrence; bSee
Table III for a detailed list.
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Figure 4). MSA was most frequently raised in patients with
disorders of the liver or gastrointestinal system (Table III,
Figure 4). Levels >300IU were seen in patients with
hepatitis (57%), cirrhosis (62%), pancreatic disorders (43%)
and gastrointestinal disorders (30%). Median levels of MSA
in non-malignant diseases were in general low, exceptions
being the groups of patients with hepatitis (306IU), and
cirrhosis (657IU). As expected, raised levels of CEA were
seen in non-malignant conditions of the lung, liver and
gastrointestinal system (Table III).
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Figure 4 Levels of MSA in serum from patients with non-
malignant disorders. Groups (listed from the left) are (i) benign
tumours, (ii) chronic and acute hepatitis, (iii) biliary and hepatic
cirrhosis, (iv) lung disorders, (v) gastrointestinal disorders, (vi)
systemic disorders, (vii) acute and chronic pancreatitis, (viii)
miscellaneous disorders. The cut off level of 300IU is indicated
by a horizontal line. For further detail refer to Table HI.
Panel B samples (n=120)
None of the normal individuals tested (n=50) had MSA
levels greater than the arbitrary cut off point of 300IU
(Table IV, Figure 5). In contrast, 60% of patients with
primary carcinoma of the breast (n= 10) and 88% of
patients with metastatic breast cancer (n=8) had elevated
MSA levels. Raised levels of MSA were seen in 60% (3/5)
of patients with local recurrence of breast cancer. Of the 16
individuals with no details of staging, 7 (44%) were shown
to have an elevated level of MSA. Only one of 16 patients
with non-malignant diseases had elevated MSA levels; this
patient had cirrhosis of the liver and a MSA level of 325IU.
Fifteen serum samples were tested from patients with
malignant diseases other than breast cancer (Table IV). In
total, 20% (3/15) had levels of MSA >300IU. All of these
patients had carcinoma of the lung with individual levels of
9915, 9758 and 988IU (Table IV, Figure 5).
Correlation ofMSA levels and the clinical course ofbreast
cancer (Panel C)
Serum samples were obtained from a group of 19 patients
with breast cancer over a two month to 24 month period
and their change in MSA levels compared with the clinical
response to therapy. The alterations in MSA levels are
shown in Figure 6 where the correlation of progress of the
disease and MSA level is apparent. Of these patients, 8/19
had progressing disease and 7/8 had a significant increase (a
change of +50% in MSA level was considered significant) in
the MSA value (p=0.025). In 5/19, there was no clinical
progress of the disease and MSA levels remained the same in
4/5. In 6/19, there was a complete or partial remission
induced by tamoxifen or chemotherapy and the MSA levels
fell by more than 50% in all of these. Those patients with
progressive breast cancer were significantly different
(p=0.014) from those with stable or regressing disease.
Overall there is 89% correlation of MSA variation with the
clinical course of the disease.
Discussion
This study has used a previously described competitive
enzyme immunoassay (Stacker et al., 1987) to evaluate levels
of MSA in the serum of normal individuals, patients with
malignant tumours and non-malignant diseases. The serum
analysed constituted three panels of coded samples, which
were tested blindly for MSA and for CEA. Although CEA is
not an ideal marker for breast cancer, its levels in serum
have been well established by previous workers (Steward et
al., 1974; Martin et al., 1976) and in this study serves as a
useful standard for comparing MSA to other serum markers.
Table III Levels of MSA and CEA in patients with non-malignant diseases
MSA level
Number of CEA level
Group patients Median (IU) >300IU (%) >2.5ngml1 (%)
Benign tumours 12 48 17 17
Liver disorders
i) Hepatitisa 14 306 57 50
ii) Cirrhosisb 13 657 62 62
Lung disordersc 2 118 0 50
Gastrointestinal disorders' 27 105 30 33
Systemic disorderse 14 185 50 57
Pancreatic disordersf 7 162 43 14
Miscellaneousg 8 29 0 43
'Includes acute and chronic hepatitis; bIncludes hepatic and biliary cirrhosis; cIncludes chronic
bronchitis; dIncludes diverticulosis, gastritis, colitis, duodenal ulcers and polyposis coli; 'Includes
diarrhoea, myopathy, diabetes, fever, dermatomyositis, anaemia, mycosis fungoidis; fIncludes acute
and chronic pancreatitis; "Includes polyneuritis, Hashimoto's disease, kidney transplant,
pericarditis, thyroiditis, papilloma ofthe bladder, herpes zoster.
S
U1)
0
.0 C
._
4-
._
Q
0 0
0 9
000 0
0
0
0 t 0
0 0
0
^n nnn-r
_
1302 S.A. STACKER et al.
Table IV Serum MSA levels found in the study group (Panel B)
MSA level
Number of
Group patients Median (IU) >300IU (%)
Apparently healthy blood donors 50 88 0
Non-malignant disordersa 16 83 6
Breast cancer
Primary 10 320 60
Metastatic 8 934 88
Recurrence 5 516 60
Not staged 16 179 44
Non-breast cancers
Lung 7 177 43
Otherb 8 73 0
aConsists of hepatitis (6), cirrhosis (2), benign breast diseases (8); bConsists of
carcinoma of the colon (4), cervix (1), testis (3).
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Figure 5 The levels of MSA in the serum of normal blood
donors, patients with non-malignant disorders, primary breast
cancer, metastatic breast cancer, breast cancer (not staged) and
patients with malignancies other than breast cancer. The
arbitrary cut off level of 300IU is shown by the horizontal line.
In general the serum MSA levels obtained in this study
agree with previous observations which find it elevated in
patients with localised and advanced breast cancer (Stacker
et al., 1987). The number of patients with raised levels and
average level of MSA, was also found to be similar to that
previously reported. A number of findings, however, did
arise from this study, that were not evident from the initial
work. For instance, smoking was found to cause increased
levels of MSA in normal individuals; this has also been
reported for other serum markers of breast cancer (Stevens
& Mackay, 1973). This result could explain the number of
normal individuals with levels >300IU in the initial study
(46/2400 blood donors), which on subsequent examination
had no clinical evidence of breast cancer or other disease
Figure 6 Changes in MSA levels with the clinical course of
breast cancer. Graph showing the change in MSA values over a
2-year period in a series of breast cancer patients undergoing
therapy. The patients have been classified into 3 groups
according to clinical status of disease (see text for details) which
had either progressed, stabilised or regressed.
(Stacker et al., 1987). Also, a number of patients with non-
malignant diseases had raised MSA levels. In particular,
conditions affecting the liver, pancreas and gastrointestinal
system produced elevated levels, however, in general the
levels were much lower than those found in active breast
cancer. Similar results have been found with other breast
cancer markers (Khoo & Mackay, 1973; Hayes et al., 1985).
MSA levels were also raised in a substantial number of
patients with non-breast tumours; this is not a surprising
result given the tissue distribution of the monoclonal
antibody 3E1.2 on secretory epithelium (Stacker et al.,
1985a). Levels are most frequently raised in ovarian and
lung cancer, but further studies are required to examine the
usefulness of MSA in monitoring these cancers or for
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complementing pre-existing markers. From the small number
of patients studied it appears as though the site of metastasis
does influence the level of serum MSA in advanced breast
cancer. Patients with liver or multiple metastases had higher
levels than those with bone metastases (Table I); this has
also been reported for the marker DF3 (Hayes et al., 1985).
Results of this study have also confirmed that MSA levels
would be useful for monitoring the clinical course of breast
cancer. Of 19 patients with metastatic breast cancer, 17 (89%)
had changing levels of MSA which correlated with either
progression, regression or stabilisation of disease. These
results are similar to a previous study (Stacker et al., 1987)
which showed a correlation in 34 (92%) breast cancer
patients. This compares favourably with other studies which
have shown the markers MAM-6, CEA and CA15-3 to
correlate in 79%, 42% and 74% of cases respectively
(Hilkens et al., 1987; Hayes et al., 1986).
Comparison of serum levels of MSA and CEA have
shown the former to be a better marker for breast cancer.
MSA was clearly elevated in more patients with breast
cancer than CEA, using the cut off levels of 300IU and
2.5ngml- I respectively (Table I). Substantial differences
were evident, particularly in patients anticipated to have low
volumes of tumour, i.e., breast cancer stage I and II, local
recurrence and no clinical evidence of disease (NED). In
addition, some patients with metastases also had raised MSA
levels but normal CEA levels. The additive effect of MSA
and CEA was only marginally better than for MSA alone, as
only three patients with active breast cancer had raised CEA
levels but low MSA levels. Also, no correlation could be
found between CEA and MSA in either patients with breast
cancer or non-breast tumours. It should be noted however,
that recent studies have shown that the level of another high
molecular weight serum marker for breast cancer, MAM-6,
correlates with CEA (Hilkens et al., 1987). The relevance of
this finding in distinguishing between MSA and MAM-6 is
unclear.
In summary, the results of this study show that levels of
the tumour-associated antigen MSA may be useful for the
detection and monitoring of breast cancer. Furthermore,
levels of MSA are more frequently raised in breast cancer
than CEA, although they appear to be elevated in a similar
number of patients with non-breast tumours and non-
malignant disorders. This study has also identified a number
of non-malignant disorders in which MSA levels are slightly
elevated, and it is important that these are taken into
consideration when assessing the overall usefulness of MSA
levels.
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